Welcome to the UPF Digital Repository

Frequency of anticancer drug use at the end of life: a scoping review

Show simple item record

dc.contributor.author Szigethy, Endre
dc.contributor.author Dorantes, Rosario
dc.contributor.author Sugrañes Martínez, Miguel
dc.contributor.author Madera, Meisser
dc.contributor.author Solà Arnau, Ivan
dc.contributor.author Urrútia, Gerard
dc.contributor.author Bonfill, Xavier
dc.date.accessioned 2024-02-28T08:03:14Z
dc.date.available 2024-02-28T08:03:14Z
dc.date.issued 2024
dc.identifier.citation Szigethy E, Dorantes R, Sugrañes M, Madera M, Sola I, Urrútia G, Bonfill X. Frequency of anticancer drug use at the end of life: a scoping review. Clin Transl Oncol. 2024 Jan;26(1):178-89. DOI: 10.1007/s12094-023-03234-1
dc.identifier.issn 1699-048X
dc.identifier.uri http://hdl.handle.net/10230/59275
dc.description.abstract Purpose: Anticancer drug use at the end of life places potential extra burdens on patients and the healthcare system. Previous articles show variability in methods and outcomes; thus, their results are not directly comparable. This scoping review describes the methods and extent of anticancer drug use at end of life. Methods: Systematic searches in Medline and Embase were conducted to identify articles reporting anticancer drug use at the end of life. Results: We selected 341 eligible publications, identifying key study features including timing of research, disease status, treatment schedule, treatment type, and treatment characteristics. Among the subset of 69 articles of all cancer types published within the last 5 years, we examined the frequency of anticancer drug use across various end of life periods. Conclusion: This comprehensive description of publications on anticancer drug use at end of life underscores the importance of methodological factors when designing studies and comparing outcomes.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Springer
dc.relation.ispartof Clin Transl Oncol. 2024 Jan;26(1):178-89
dc.rights © The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Frequency of anticancer drug use at the end of life: a scoping review
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1007/s12094-023-03234-1
dc.subject.keyword Anticancer agents
dc.subject.keyword Medical overuse
dc.subject.keyword Neoplasms
dc.subject.keyword Terminal care
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking